MYRIAD GENETICS INC. - COMMON STOCK

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

16 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

10 5 2024 08:45:09 提供 NetDania Notify

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

09 5 2024 08:49:28 提供 NetDania Notify

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

07 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

07 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

30 4 2024 15:05:00 提供 Nasdaq GlobeNewswire

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

17 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

16 4 2024 08:15:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

09 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 3 2024 20:40:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 2 2024 15:05:01 提供 Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 2 2024 08:15:00 提供 Nasdaq GlobeNewswire

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

21 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

15 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

01 2 2024 08:25:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

30 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

18 1 2024 17:10:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

09 1 2024 15:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 15:05:00 提供 Nasdaq GlobeNewswire